These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1678611)

  • 1. L-dopa potentiating analogs of Pro-Leu-Gly-NH2 with oral efficacy.
    Albrecht HP; Hofman HP; Klebe G; Kreiskott H
    Boll Chim Farm; 1991 Feb; 130(2):55-9. PubMed ID: 1678611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP
    Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
    [No Abstract]   [Full Text] [Related]  

  • 3. Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG).
    Mishra RK; Marcotte ER; Chugh A; Barlas C; Whan D; Johnson RL
    Peptides; 1997; 18(8):1209-15. PubMed ID: 9396063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure activity relationship studies with hypothalamic peptide hormones. I. Effect of melanotropin release inhibiting factor and analogs on tolerance to morphine in the rat.
    Bhargava HN; Kim HS
    J Pharmacol Exp Ther; 1982 Feb; 220(2):394-8. PubMed ID: 6120229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
    Björkman S; Castensson S; Lindeke B; Sievertsson H
    Acta Pharm Suec; 1976; 13(4):289-98. PubMed ID: 11638
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
    Voith K
    Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of Pro-Leu-Gly-NH2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN.
    Johnson RL; Rajakumar G; Yu KL; Mishra RK
    J Med Chem; 1986 Oct; 29(10):2104-7. PubMed ID: 2876104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring alpha,alpha-disubstituted amino acids.
    Evans MC; Pradhan A; Venkatraman S; Ojala WH; Gleason WB; Mishra RK; Johnson RL
    J Med Chem; 1999 Apr; 42(8):1441-7. PubMed ID: 10212130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease].
    Pan JB
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):205-8. PubMed ID: 2866940
    [No Abstract]   [Full Text] [Related]  

  • 10. Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease.
    Case TC; Snider SR; Hruby VJ; Rockway T
    Life Sci; 1985 Jul; 36(26):2531-7. PubMed ID: 2861549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of L-prolyl-L-leucyl-glycinamide (PLG): a review.
    Mishra RK; Chiu S; Chiu P; Mishra CP
    Methods Find Exp Clin Pharmacol; 1983; 5(4):203-33. PubMed ID: 6136640
    [No Abstract]   [Full Text] [Related]  

  • 12. Structural specificity of MIF-1 and Tyr-MIF-1 in augmenting GABA-stimulated benzodiazepine receptor binding.
    Miller LG; Kastin AJ; Roy RB; Gaver A; Fischman AJ; Horvath A
    Res Commun Chem Pathol Pharmacol; 1988 Nov; 62(2):365-8. PubMed ID: 2908009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of analogues of Pro-Leu-Gly-NH2 modified at the leucyl residue.
    Johnson RL; Bontems RJ; Yang KE; Mishra RK
    J Med Chem; 1990 Jun; 33(6):1828-32. PubMed ID: 1971310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide.
    Baures PW; Ojala WH; Costain WJ; Ott MC; Pradhan A; Gleason WB; Mishra RK; Johnson RL
    J Med Chem; 1997 Oct; 40(22):3594-600. PubMed ID: 9357526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
    Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
    Xu DL; Yu WC; Pan GB; Chen SD
    Adv Neurol; 1987; 45():587-90. PubMed ID: 2881450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and conformational study of two L-prolyl-L-leucyl-glycinamide analogues with a reduced peptide bond.
    Vander Elst P; Elseviers M; De Cock E; Van Marsenille M; Tourwé D; Van Binst G
    Int J Pept Protein Res; 1986 Jun; 27(6):633-42. PubMed ID: 2875969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man.
    Barbeau A
    Lancet; 1975 Oct; 2(7937):683-4. PubMed ID: 52054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.